The Fort Worth Press - Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Results

USD -
AED 3.672498
AFN 64.999798
ALL 82.324126
AMD 360.439737
ANG 1.790403
AOA 917.999825
ARS 1543.774978
AUD 1.480635
AWG 1.8
AZN 1.699363
BAM 1.774194
BBD 2.019595
BDT 124.714249
BGN 1.77347
BHD 0.378283
BIF 3011.049223
BMD 1
BND 1.291133
BOB 11.706702
BRL 5.686902
BSD 1.002676
BTN 94.445982
BWP 14.014686
BYN 3.004037
BYR 19600
BZD 2.016692
CAD 1.42842
CDF 2315.00023
CHF 0.840095
CLF 0.025417
CLP 1000.480332
CNY 6.67175
CNH 6.66782
COP 3316.61
CRC 449.312832
CUC 1
CUP 24.064734
CVE 100.026761
CZK 22.18975
DJF 178.554905
DKK 6.790305
DOP 60.996961
DZD 137.014347
EGP 53.649023
ERN 15
ETB 164.576405
EUR 0.90831
FJD 2.280098
FKP 0.756558
GBP 0.75785
GEL 2.590074
GGP 0.756558
GHS 11.756648
GIP 0.756558
GMD 74.000006
GNF 8883.828946
GTQ 7.665407
GYD 209.778157
HKD 7.84665
HNL 26.963428
HRK 6.831965
HTG 131.493006
HUF 331.23032
IDR 18267.95
ILS 3.22225
IMP 0.756558
INR 93.92255
IQD 1520.102326
IRR 1913737.523681
ISK 124.069717
JEP 0.756558
JMD 158.434973
JOD 0.70902
JPY 159.523499
KES 130.039569
KGS 87.449397
KHR 4119.418691
KMF 447.000366
KPW 900.00035
KRW 1335.070061
KWD 0.31151
KYD 0.835571
KZT 446.941108
LAK 22570.768945
LBP 89792.715562
LKR 333.502667
LRD 170.460782
LSL 16.951345
LTL 2.95274
LVL 0.60489
LYD 6.463464
MAD 9.936772
MDL 18.213733
MGA 4555.721867
MKD 55.90096
MMK 2099.568705
MNT 3604.028735
MOP 8.103614
MRU 40.552456
MUR 47.809885
MVR 15.396662
MWK 1738.739965
MXN 18.573803
MYR 4.093898
MZN 63.899938
NAD 16.951268
NGN 1347.489819
NIO 36.903315
NOK 9.600095
NPR 151.114437
NZD 1.81263
OMR 0.384508
PAB 1.002667
PEN 3.411771
PGK 4.5757
PHP 63.963967
PKR 277.274459
PLN 4.00014
PYG 6223.068898
QAR 3.655265
RON 4.859302
RSD 106.818993
RUB 82.553706
RWF 1483.473867
SAR 3.763142
SBD 8.097697
SCR 13.770647
SDG 601.516238
SEK 10.079445
SGD 1.2891
SHP 0.752984
SLE 23.050274
SLL 20969.503664
SOS 573.051087
SRD 37.49018
STD 20697.981008
STN 22.225347
SVC 8.773903
SYP 13002.000337
SZL 16.945524
THB 33.901027
TJS 9.24984
TMT 3.5
TND 3.022529
TOP 2.40776
TRY 50.392297
TTD 6.806306
TWD 32.943501
TZS 2651.477006
UAH 45.588969
UGX 4141.134208
UYU 40.639897
UZS 12057.766973
VES 912.87925
VND 25764
VUV 120.719595
WST 2.810584
XAF 595.812425
XAG 0.021002
XAU 0.000258521515
XCD 2.70255
XCG 1.807123
XDR 0.707052
XOF 595.812425
XPF 108.186074
YER 236.549829
ZAR 16.951101
ZMK 9001.197322
ZMW 20.500748
ZWL 321.999592
SSP 5945.381189
MXV 2.084233
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Results
Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Results

Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Results

Mipletamig achieves 79% remission rate in high-risk TP53-mutated AML, nearly double the published historical benchmark

Ten of 47 patients receiving mipletamig combination therapy advances to potentially curative stem cell transplantation

Refined priming-dose regimen significantly reduces infusion-related reactions, marking important tolerability advance

Aptevo advances next generation trispecifics toward human testing, expanding opportunities beyond AML

Text size:

SEATTLE, WA / ACCESS Newswire / November 16, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today reported financial results for the quarter ended September 30, 2026, and highlighted new clinical findings supporting mipletamig's potential in frontline acute myeloid leukemia (AML), progress in optimizing treatment tolerability, and continued advancement of its next-generation cancer treatment pipeline.

"We are entering an exciting period for Aptevo, with growing clinical evidence that reinforces our confidence in mipletamig and meaningful progress across our broader pipeline," said Jeff Lamothe, President and Chief Executive Officer of Aptevo. "We are seeing strong clinical activity in patients with some of the most difficult-to-treat forms of AML, patients advancing to potentially curative stem cell transplantation, and important improvements in tolerability. Each of these findings adds a new dimension to the mipletamig story and strengthens our conviction in its potential to become an important addition to frontline AML treatment. At the same time, we are advancing a new generation of cancer therapies designed to bring the power of our multispecific technology to more patients and more types of cancer. As we approach important clinical and development milestones, we believe Aptevo is increasingly well positioned to translate the strength of our science into meaningful opportunities for patients and long-term value for shareholders."

Business Highlights

  • Mipletamig delivers a 79% remission rate in one of the hardest-to-treat forms of AML, nearly double a published historical benchmark. In September, Aptevo reported that 14 evaluable TP53-mutated patients treated with mipletamig in combination with venetoclax and azacitidine, including two patients from the previously completed dose expansion trial, 13 (93%) experienced clinical benefit. * Eleven patients achieved CR or CRi (79%), including nine complete remissions.

*Clinical benefit includes complete remission (CR), complete remission with incomplete hematologic recovery (CRi), partial response (PR) and morphologic leukemia-free state (MLFS).

These results are encouraging because patients with TP53-mutated AML have historically had limited treatment success. The 79% CR/CRi rate observed in evaluable patients treated with the mipletamig triplet compares favorably with a published 41% composite remission rate of intent-to-treat, treatment-naïve patients with poor-risk cytogenetics and TP53-mutated AML who received only venetoclax plus azacitidine.**

**Benchmark comparison based on Pollyea DA, et al. Clinical Cancer Research 2022;28(24):5272-5279. Comparison is to treatment-naïve patients with poor-risk cytogenetics and TP53-mutated AML treated with venetoclax plus azacitidine.

  • Ten of 47 patients receiving mipletamig combination therapy advances to potentially curative stem cell transplantation. In October, Aptevo reported that ten of 47 evaluable frontline patients treated with mipletamig in combination with venetoclax and azacitidine (VEN+AZA) proceeded to allogeneic stem cell transplantation, a potentially curative treatment option. This includes nine patients from the ongoing Phase 1b RAINIER trial and one patient from the previously completed dose expansion trial. This finding is particularly encouraging in a patient population initially deemed unfit for intensive induction chemotherapy, where advanced age, underlying health conditions and other factors can limit treatment options.
  • Aptevo significantly reduced infusion-related reactions through refinements to mipletamig's priming-dose regimen. The adjustment substantially improved tolerability, addressing an important clinical development priority. For patients already facing the challenges of AML treatment, fewer reactions may mean a more manageable treatment experience, while supporting continued advancement toward Phase 2.
  • Mipletamig approaches a major development milestone as RAINIER nears completion of Phase 1b dose optimization. With study completion targeted by year-end 2026 and regulatory interaction planned for the first half of 2027, Aptevo is moving closer to the next phase of clinical development, bringing mipletamig another step toward its potential role in frontline AML treatment.
  • Aptevo clears important development hurdles on the path toward human testing of its next generation trispecifics. Progress in manufacturing optimization supports the ability to produce therapeutics that perform more than one immune engaging job in a single molecule - reliably and at the scale needed for further development. This moves Aptevo closer to advancing new treatment candidates for solid tumors, expanding its opportunities beyond AML.
  • Aptevo expands the potential of its technology to power multiple new cancer treatments. A new patent application covering Nectin-4 × PD-L1 dual-targeting technology could support both immune-based therapies and radiopharmaceuticals. The filing strengthens Aptevo's intellectual property strategy, creating opportunities to apply its technology across multiple cancer treatment approaches.
  • Aptevo secures $4.5 million in additional financing to support its next development milestones. In August, existing warrant holders exercised warrants for 254,922 shares at a price of $4.03 per share and purchased 861,708 additional shares (or pre-funded warrants) at the same price in a private placement. Investors also received new warrants covering up to 5,583,150 shares at $4.03 per share, which would provide up to $22.5 million in additional proceeds if exercised. The transaction provides additional capital to advance mipletamig and the Company's next-generation pipeline, helping fund continued clinical and preclinical progress.

Third Quarter 2026 Financials

  • Cash position: Cash and cash equivalents totaled $8.3 million as of September 30, 2026, compared with $9.8 million as of June 30, 2026.
  • Net loss: Net loss for the third quarter of 2026 was $6.5 million, compared with $7.5 million for the third quarter of 2025.
  • Financing activity: In August 2026, the company completed a warrant inducement and private placement that generated gross proceeds of approximately $4.5 million, or approximately $4.1 million net of $0.4 million in issuance costs.
  • For additional APVO financial information and complete access to the company's filings, click here.

About Aptevo

Aptevo Therapeutics Inc. (Nasdaq:APVO) is a clinical-stage biotechnology company focused on developing novel bispecific and trispecific immunotherapies for the treatment of cancer. The Company's lead clinical candidate, mipletamig, is currently being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax and azacitidine. Mipletamig has received orphan drug designation for AML under the Orphan Drug Act.

In the solid tumor space, Aptevo's lead assets are focused on well-established targets to progress novel immunomodulatory platform backbones that are conditionally active only in the tumor.

This work includes advancing APVO451, a targeted trispecific immunotherapy candidate for solid tumors, and a strategic collaboration with Niowave to develop up to three radiopharmaceutical oncology programs. The first radiopharmaceutical program is expected to target nectin-4, a tumor-associated antigen expressed in multiple solid tumor types. Both preclinical molecules are expected to advance into investigational new drug (IND)-enabling studies in 2027.

The Company's eight pipeline candidates are created using its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platforms, which are designed to generate differentiated multispecific therapeutics. For more information, please visit www.aptevotherapeutics.com.

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, statements regarding Aptevo's expectations about the activity, efficacy, safety, tolerability and durability of mipletamig, including in combination with venetoclax and azacitidine; statements related to the progress of the RAINIER trial, including statements related to anticipated clinical and regulatory milestones; statements related to a growing number of patients treated with the mipletamig triplet advancing to stem cell transplant and mipletamig's role in offering AML patients the possibility of long-term remission or cure, statements related to the responses observed in patients with TP53-mutated AML and whether further study of mipletamig in combination with venetoclax + azacitidine will continue to show clinical benefit in patients with TP53-mutated AML; whether Aptevo's strategy will translate into an improved overall survival rate in acute myeloid leukemia (AML); whether the mipletamig data in combination therapy will be indicative of later stage clinical trials; whether Aptevo's strategy will translate into improved overall survival in AML, especially among patient subgroups with poor prognosis; its expectations regarding the effectiveness of its ADAPTIR and ADAPTIR-FLEX platform; development and continued development of Aptevo's current and potential future molecules, including Aptevo's trispecific candidates and their future development and efficacy with respect to addressing multiple solid tumor types; whether pre-clinical studies of Aptevo's trispecific candidates will show the desired anti-tumor efficacy, mechanism of action and safety profile and whether Aptevo's trispecific candidates will function with new mechanisms of action compared to our previous candidates and synergistically induce a biological response; the potential benefits, timing, scope and outcomes of the co-development collaboration with Niowave; and any statements containing the words "may," "continue to," "believes," "expects," "potential," "designed," "promising," "plans," "will" and similar expressions are intended to identify forward-looking statements.

These forward-looking statements are based on Aptevo's current intentions, beliefs and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors are cautioned not to place undue reliance on any forward-looking statement. There are several important factors that could cause Aptevo's actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo's business or prospects; further assessment of preliminary or interim data or different results from later clinical trials; adverse events and unanticipated problems; adverse developments in clinical development, including unexpected safety issues observed during a clinical trial; and changes in regulatory, social, macroeconomic and political conditions. Additional risks and factors that may affect results are set forth in Aptevo's filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026, and its subsequent reports on Form 10-Q and current reports on Form 8-K. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not assume any obligation to update any forward-looking statement to reflect new information, events or circumstances.

CONTACT:

Miriam Weber Miller
Vice President, Investor Relations & Corporate Communications
Aptevo Therapeutics
Email: [email protected] or [email protected]
Phone: 206-859-6628

SOURCE: Aptevo Therapeutics



View the original press release on ACCESS Newswire

K.Ibarra--TFWP